Quantcast
Last updated on April 17, 2014 at 11:00 EDT

Latest Duchenne muscular dystrophy Stories

2012-06-25 02:26:07

Meeting to Take Place at Annual Connect Conference in Ft. Lauderdale HACKENSACK, N.J., June 25, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) will host the first Transforming Duchenne Care Meeting, June 27-28, 2012, immediately preceding the Annual Connect Conference in Fort Lauderdale, Florida. The goal of the Transforming Duchenne Care Meeting is to bring together leadership from top medical institutions, neuromuscular experts, and patient representatives to...

2012-06-22 11:52:36

'A Molecular Bandage for Diseased Muscle' appears today in prestigious Science publication Leading muscular dystrophy researcher Dean Burkin, of the University of Nevada School of Medicine summarizes the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy in an article published this week in Science Translational Medicine. "This is a focus article in which we summarize the impact of MG53 protein therapy as a treatment option and discuss the...

2012-06-20 10:23:04

HACKENSACK, N.J., June 20, 2012 /PRNewswire-USNewswire/ -- AVI BioPharma is teaming up with Parent Project Muscular Dystrophy (PPMD)'s endurance program, Run For Our Sons, to participate in the Rock 'n' Roll Seattle Marathon & Half Marathon on June 23, 2012. The goal is to raise money and awareness to help end Duchenne muscular dystrophy (Duchenne), the most common form of muscular dystrophy. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO) AVI and PPMD have a long...

2012-06-13 10:23:58

Letter Signed by Nearly 120 Organizations, Latest PDUFA-Oriented Action HACKENSACK, N.J., June 13, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the nation's largest Duchenne muscular dystrophy (Duchenne) advocacy organization - co-led a letter to key lawmakers that was signed by 119 organizations and that urges Congress to include the strongest patient engagement and rare disease provisions within the final use fee legislation. (Logo:...

2012-06-11 23:00:42

HUNTINGTON´S DISEASE, for the FIRST time in history was treated in March 2012 by Dr.´s Feinerman and Paino in our state of the art clinic in Lima, Peru. Two sisters with this debilitating disease will be followed over the next year after a very successful treatment. You can follow the progress and see other testimonials on our website, http://www.stemcellregenmed.com Aventura, North Miami, Florida (PRWEB) June 11, 2012 In a time of such an amazing biotechnology medical era in...

2012-05-24 06:28:45

HACKENSACK, N.J., May 24, 2012 /PRNewswire-USNewswire/ -- As the U.S. Senate continues debate on legislation that seeks to accelerate delivery of safe and effective therapies to patients and to increase the patient voice as part of the therapy review process, Parent Project Muscular Dystrophy (PPMD) is pleased to offer its enthusiastic endorsement of the legislation. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO) Over the past several months, PPMD - the leading...

2012-05-22 02:27:43

NEWTON, Mass., May 22, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that it has received financial support totaling $1.1 million from 12 not-for-profit foundations serving the muscular dystrophy patient community. Halo will use the funds to expedite the phase 2 study of HT-100, its lead drug candidate for Duchenne muscular dystrophy (DMD). HT-100, a proprietary formulation of...

2012-05-03 06:27:12

Larger Community Roundtable on Trial Design Planned HACKENSACK, N.J., May 3, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) - the leading advocacy organization fighting to end Duchenne muscular dystrophy, the most common form of muscular dystrophy, convened a high-impact meeting with leaders of the Food & Drug Administration's (FDA) drug review center to seek ways to accelerate the review process and to ensure the patient voice is included when key decisions...

2012-05-03 02:31:18

Muscular Dystrophy Association has awarded ReveraGen BioPharma $1.5 million to develop drug TUCSON, Ariz., May 3, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association announced today that it has awarded $1,549,725 to ReveraGen BioPharma, a Rockville, Md., biotechnology company, to develop and test a "dissociative glucocorticoid" as a potential treatment for Duchenne muscular dystrophy (DMD). (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) MDA has...

2012-04-24 06:26:30

Louisiana's Tim Rice Begins Trek to Raise Duchenne Awareness HACKENSACK, N.J., April 24, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) is proud to announce that Tim Rice, a resident of Louisiana's Northshore, will be hiking the Pacific Crest Trail on PPMD's behalf, beginning April 23, 2012. Tim will hike at least 500 miles raising awareness for Duchenne muscular dystrophy, as well as money to support critical research. (Logo:...